On February 14, the US Food and Drug Administration (FDA) approved vimseltinib, a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumors for which surgical resection will potentially cause worsening functional limitation or severe morbidity. 

For more information, read the FDA announcement and the Deciphera press release.

Posted on 2/17/25